Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 3/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | NAT1 | P18440 | 1/20 | 0.35 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414679 | 0.86 | PTGDR2 (0.43) | PTGDR2PIK3C3HTR6SRCBRD4 | |
| SCHEMBL30135168 | 0.83 | CYP2C19 (0.46) | PIK3C3KLKB1HTR6CYP2C19 | |
| SCHEMBL13505139 | 0.79 | PTGDR2 (0.46) | PTGDR2PIK3C3CA12CA2CA9 | |
| SCHEMBL30135084 | 0.78 | ALDH1A1 (0.45) | PTGDR2PIK3C3HTR6 | |
| SCHEMBL13241043 | 0.76 | PTGDR2 (0.42) | PTGDR2PIK3C3HTR6SRCBRD4 | |
| SCHEMBL1154907 | 0.75 | PTGDR2 (0.48) | PTGDR2PIK3C3HTR6SRCBRD4 | |
| SCHEMBL29959159 | 0.75 | PTGDR2 (0.48) | PTGDR2PIK3C3HTR6SRCBRD4 | |
| SCHEMBL30135049 | 0.75 | PTGDR2 (0.48) | PTGDR2PIK3C3HTR6SRCBRD4 | |
| SCHEMBL470184 | 0.75 | PTGDR2 (0.48) | PTGDR2PIK3C3HTR6SRCBRD4 | |
| SCHEMBL13981369 | 0.75 | PTGDR2 (0.48) | PTGDR2PIK3C3HTR6SRCBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| WO-2022216717-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | PTGDR2 3503/4885PIK3C3 734/4885CA12 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.